169 related articles for article (PubMed ID: 38486172)
41. Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
Sato J; Uchida M; Wakabayashi H; Shimizu T
Anticancer Res; 2022 Jun; 42(6):3109-3116. PubMed ID: 35641286
[TBL] [Abstract][Full Text] [Related]
42. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
43. Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database.
Yamashiro K; Jouta M; Hosomi K; Yokoyama S; Ozaki Y; Hirata A; Ogata F; Nakamura T; Tanei S; Kawasaki N
Sci Rep; 2022 Oct; 12(1):17652. PubMed ID: 36271126
[TBL] [Abstract][Full Text] [Related]
44. Adverse Effects of Kampo Medicines.
Shimada Y
Intern Med; 2022 Jan; 61(1):29-35. PubMed ID: 33551404
[TBL] [Abstract][Full Text] [Related]
45. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
Hosohata K; Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K
Clin Drug Investig; 2019 Apr; 39(4):363-368. PubMed ID: 30689189
[TBL] [Abstract][Full Text] [Related]
46. [Adverse Event Trends Associated with Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event Report Database].
Sasaoka S; Hatahira H; Hasegawa S; Motooka Y; Fukuda A; Naganuma M; Umetsu R; Nakao S; Shimauchi A; Ueda N; Hirade K; Iguchi K; Nakamura M
Yakugaku Zasshi; 2018; 138(1):123-134. PubMed ID: 29311458
[TBL] [Abstract][Full Text] [Related]
47. Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database.
Kose E
J Clin Pharm Ther; 2018 Aug; 43(4):543-549. PubMed ID: 29574893
[TBL] [Abstract][Full Text] [Related]
48. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database.
Inoue M; Matsumoto K; Tanaka M; Yoshida Y; Satake R; Goto F; Shimada K; Mukai R; Hasegawa S; Suzuki T; Ikesue H; Liao J; Hashida T; Nakamura M
Sci Rep; 2021 May; 11(1):11324. PubMed ID: 34059747
[TBL] [Abstract][Full Text] [Related]
49. Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease.
Udagawa C; Horinouchi H; Shiraishi K; Kohno T; Okusaka T; Ueno H; Tamura K; Ohe Y; Zembutsu H
PLoS One; 2019; 14(10):e0223371. PubMed ID: 31584970
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
51. Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database.
Hatano M; Yamada K; Matsuzaki H; Yokoi R; Saito T; Yamada S
PLoS One; 2023; 18(6):e0287122. PubMed ID: 37307250
[TBL] [Abstract][Full Text] [Related]
52. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
[TBL] [Abstract][Full Text] [Related]
53. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Hasegawa S; Matsui T; Hane Y; Abe J; Hatahira H; Motooka Y; Sasaoka S; Fukuda A; Naganuma M; Hirade K; Takahashi Y; Kinosada Y; Nakamura M
PLoS One; 2017; 12(7):e0182045. PubMed ID: 28732067
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
[TBL] [Abstract][Full Text] [Related]
55. The Influence of the Rapid Increase in the Number of Adverse Event Reports for COVID-19 Vaccine on the Disproportionality Analysis Using JADER.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Shimizu T
In Vivo; 2023; 37(1):345-356. PubMed ID: 36593055
[TBL] [Abstract][Full Text] [Related]
56. Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database.
Takeyama M; Sai K; Imatoh T; Segawa K; Hirasawa N; Saito Y
Biol Pharm Bull; 2017; 40(9):1447-1453. PubMed ID: 28867727
[TBL] [Abstract][Full Text] [Related]
57. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
58. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
59. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
